CYTEA|BIO is a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies. The company has developed and patented the Pin™ platform, a versatile and modular cell therapy platform enabling the combination of unmodified immune effector cells and targeting ligands. CYTEA|BIO is the first pipeline company of MedXCell.
This website contains information about products that may not be available in all countries, available under different trademarks or for different indications. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development and described on this site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider
© All rights reserved 2022 – MedXCell SA